Pancreatic cancer
Programs in the registry with at least one linked ClinicalTrials.gov trial in pancreatic cancer (the trial's conditions or title mention it): 42 programs, 80 trials. Only confirmed (automatic) trial links are counted; each program's page has the rest.
Adenoviridae
Oncolytic
Ad5-yCD/mutTKSR39rep-hIL12 AXP000048
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT03281382 | Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer | Phase 1 | Completed | 2017-07-01 |
CAdVEC AXP000042
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | Phase 1 | Recruiting | 2020-12-14 |
delolimogene mupadenorepvec AXP000007 · LOAd703, Oncolytic Adenovirus LOAd703
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | Phase 1/2 | Completed | 2018-03-01 |
| NCT02705196 | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | Phase 1/2 | Completed | 2016-11 |
H101 AXP000003 · Oncorine, Oncolytic Adenovirus H101, rAd5 H101
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT06196671 | Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer | Phase 2 | Not yet recruiting | 2026-12-01 |
| NCT05303090 | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer | Phase 1 | Completed | 2022-03-31 |
MEM-288 AXP000041
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | Phase 1 | Recruiting | 2022-04-21 |
NG-350A AXP000038
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT04787991 | Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | Phase 1 | Completed | 2021-08-09 |
zabilugene almadenorepvec AXP000008 · VCN-01
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT07701486 | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer | Phase 1/2 | Recruiting | 2026-07-31 |
| NCT05673811 | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer | Phase 2 | Completed | 2023-01-10 |
| NCT05057715 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | Phase 1 | Terminated | 2022-03-02 |
| NCT02045602 | Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | Phase 1 | Completed | 2014-01 |
| NCT02045589 | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | Phase 1 | Completed | 2014-01 |
In vivo gene transfer
aglatimagene besadenovec AXP000144 · GliAtak, ProstAtak, Virafir
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT02446093 | Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Unknown | 2015-10 |
| NCT00638612 | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) | Phase 1 | Completed | 2008-08 |
golnerminogene pradenovec AXP000150 · TNFerade, ADgv EGR.TNF.11D
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT00051467 | A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer | Phase 3 | Completed |
Vaccine vector
ETBX-011 AXP000154
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Phase 2 | Withdrawn | 2018-08 |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | Phase 1/2 | Terminated | 2018-07-17 |
| NCT03387098 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Phase 1/2 | Terminated | 2017-12-28 |
| NCT03329248 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Phase 1/2 | Terminated | 2017-11-06 |
| NCT03136406 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Phase 1/2 | Terminated | 2017-08-11 |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | Phase 1/2 | Terminated | 2017-06-26 |
ETBX-021 AXP000155
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Phase 2 | Withdrawn | 2018-08 |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | Phase 1/2 | Terminated | 2018-07-17 |
ETBX-051 AXP000156
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Phase 2 | Withdrawn | 2018-08 |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | Phase 1/2 | Terminated | 2018-07-17 |
ETBX-061 AXP000157
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Phase 2 | Withdrawn | 2018-08 |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | Phase 1/2 | Terminated | 2018-07-17 |
GRT-C903 AXP000162
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Phase 1/2 | Completed | 2019-07-18 |
Orthoherpesviridae
Oncolytic
canerpaturev AXP000076 · HF10, TBI-1401, C-REV
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT03252808 | Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer. | Phase 1 | Active not recruiting | 2017-09-25 |
OH2 AXP000089 · OH2 injection, oHSV2hGM-CSF
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT04637698 | OH2 Oncolytic Viral Therapy in Pancreatic Cancer | Phase 1/2 | Terminated | 2021-02-02 |
OrienX010 AXP000077
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT01935453 | A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer | Phase 1 | Completed | 2012-05 |
R130 AXP000091
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | Early phase 1 | Unknown | 2023-03-30 |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | Early phase 1 | Unknown | 2023-03-02 |
STI-1386 AXP000135 · Seprehvec, Oncolytic HSV-1 STI-1386
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT05361954 | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | Phase 1 | Not yet recruiting | 2023-08 |
talimogene laherparepvec AXP000001 · Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT03086642 | Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer | Phase 1 | Completed | 2017-11-16 |
| NCT00402025 | Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer | Phase 1 | Completed | 2006-11 |
VG161 AXP000082 · Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT05162118 | Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer | Phase 1/2 | Unknown | 2022-03-08 |
Parvoviridae
Oncolytic
ParvOryx AXP000127
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT02653313 | Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer | Phase 1/2 | Completed | 2015-12 |
Poxviridae
Oncolytic
GC001 AXP000108
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT06508307 | A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors | Phase 1 | Recruiting | 2023-04-26 |
hV01 AXP000103 · Recombinant human IL-21-expressing oncolytic vaccinia virus injection
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT07006077 | Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer | Phase 2 | Recruiting | 2025-05-29 |
IDOV-Immune AXP000110
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | Phase 1 | Recruiting | 2025-08-25 |
JX-929 AXP000097 · vvDD-CDSR
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT00574977 | Safety Study of Modified Vaccinia Virus to Cancer | Phase 1 | Completed | 2008-05 |
Vaccine vector
CV301 AXP000180 · CV301-V/F, CVAC-301, FPV-CV301
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | Phase 1/2 | Terminated | 2018-08-08 |
p53MVA AXP000187 · MVA-p53
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Phase 1 | Active not recruiting | 2015-12-28 |
| NCT01191684 | Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer | Phase 1 | Completed | 2011-12-22 |
PANVAC AXP000179 · falimarev, inalimarev, PANVAC-F
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT00669734 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | Phase 1 | Active not recruiting | 2010-02-01 |
| NCT00088660 | PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen | Phase 3 | Unknown | 2004-06 |
Retroviridae
Oncolytic
vocimagene amiretrorepvec AXP000126 · Toca 511
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | Phase 1 | Terminated | 2016-07 |
In vivo gene transfer
Rexin-G AXP000210 · Mx-dnG1, DeltaRex-G, Retrovector Encoding Mutant Anti-Cyclin G1
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT00504998 | Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer | Phase 1/2 | Completed | 2007-07 |
| NCT00121745 | Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer | Phase 1 | Terminated | 2005-07 |
Spinareoviridae
Oncolytic
pelareorep AXP000004 · Reolysin, PO-BB0209
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | Phase 1/2 | Active not recruiting | 2021-10-27 |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | Phase 2 | Terminated | 2018-11-14 |
| NCT02620423 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | Phase 1 | Completed | 2015-12 |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | Phase 2 | Completed | 2010-12 |
| NCT00998322 | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | Phase 2 | Completed | 2009-10 |
Togaviridae
Oncolytic
VRT106 AXP000128
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT06758544 | A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer | Phase 1/2 | Recruiting | 2025-03-17 |
| NCT06866977 | A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer | Phase 1/2 | Not yet recruiting | 2025-03-12 |
Vaccine vector
AVX701 AXP000213 · CEA(6D) VRP
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT00529984 | A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies | Phase 1/2 | Completed | 2007-09 |
Targeted small molecule
adagrasib AXP000024 · Krazati, MRTX849
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT06130254 | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | Phase 1 | Terminated | 2024-01-30 |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Phase 1 | Recruiting | 2023-10-18 |
| NCT05634525 | Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients | Phase 1 | Withdrawn | 2023-05-03 |
daraxonrasib AXP000027 · Rasonque, RMC-6236
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT07898813 | Daraxonrasib in Resectable PDAC | Phase 1 | Not yet recruiting | 2027-04-13 |
| NCT07895498 | A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer | Phase 2 | Recruiting | 2026-10-16 |
| NCT07756281 | First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer | Phase 1 | Recruiting | 2026-09-01 |
| NCT07805954 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma | Phase 3 | Recruiting | 2026-08-28 |
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | 2026-03-09 |
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Phase 1 | Recruiting | 2026-01-08 |
| NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 | Recruiting | 2025-12-15 |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Phase 1/2 | Recruiting | 2025-05-31 |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 | Active not recruiting | 2024-10-16 |
| NCT06360354 | A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) | Phase 1 | Active not recruiting | 2024-05-29 |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Recruiting | 2024-05-24 |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Phase 1/2 | Recruiting | 2023-11-14 |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Recruiting | 2023-09-07 |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Phase 1/2 | Recruiting | 2022-05-31 |
| NCT07573215 | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma | Approved for marketing |
elironrasib AXP000028 · RMC-6291
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Phase 1/2 | Recruiting | 2023-11-14 |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | Phase 1 | Active not recruiting | 2022-09-19 |
glecirasib AXP000030 · 艾瑞凯, JAB-21822
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT06008288 | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | Phase 2 | Recruiting | 2023-10-27 |
| NCT05288205 | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | Phase 1/2 | Recruiting | 2022-04-14 |
MRTX1133 AXP000026
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Phase 1 | Terminated | 2023-03-06 |
olomorasib AXP000032 · LY3537982
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Phase 1/2 | Active not recruiting | 2021-07-19 |
sotorasib AXP000023 · Lumakras, Lumykras, AMG 510
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212 | Phase 1/2 | Recruiting | 2026-03-27 |
| NCT06892054 | Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma | Phase 1 | Recruiting | 2025-08-08 |
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | Phase 1/2 | Withdrawn | 2022-09-13 |
zoldonrasib AXP000029 · RM-036, RMC-9805
| Trial | Title | Phase | Status | Start |
|---|---|---|---|---|
| NCT07805954 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma | Phase 3 | Recruiting | 2026-08-28 |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) | Phase 3 | Recruiting | 2026-05-22 |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Phase 1/2 | Recruiting | 2025-05-31 |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Recruiting | 2024-05-24 |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Recruiting | 2023-09-07 |